Dr. Stacy L. Cooper
Claim this profileJohns Hopkins University/Sidney Kimmel Cancer Center
Area of expertise
Acute Lymphoblastic Leukemia
Stacy L. Cooper has run 4 trials for Acute Lymphoblastic Leukemia. Some of their research focus areas include:
Burkitt Lymphoma
Stacy L. Cooper has run 3 trials for Burkitt Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
Johns Hopkins University/Sidney Kimmel Cancer Center
The Johns Hopkins Hospital JHH
Clinical Trials Stacy L. Cooper is currently running
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting
2 awards
Phase 3
Diagnostic Testing
for Pediatric Leukemia
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Recruiting
1 award
Phase 1 & 2
11 criteria
More about Stacy L. Cooper
Clinical Trial Related
8 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Stacy L. Cooper has experience with
- Nivolumab
- Brentuximab Vedotin
- Cyclophosphamide
- Relatlimab
- Bendamustine
- Blinatumomab
Breakdown of trials Stacy L. Cooper has run
Acute Lymphoblastic Leukemia
Burkitt Lymphoma
Hodgkin's Lymphoma
Acute Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stacy L. Cooper specialize in?
Stacy L. Cooper focuses on Acute Lymphoblastic Leukemia and Burkitt Lymphoma. In particular, much of their work with Acute Lymphoblastic Leukemia has involved Stage IV patients, or patients who are CRLF2 positive.
Is Stacy L. Cooper currently recruiting for clinical trials?
Yes, Stacy L. Cooper is currently recruiting for 5 clinical trials in Baltimore Maryland. If you're interested in participating, you should apply.
Are there any treatments that Stacy L. Cooper has studied deeply?
Yes, Stacy L. Cooper has studied treatments such as Nivolumab, Brentuximab Vedotin, Cyclophosphamide.
What is the best way to schedule an appointment with Stacy L. Cooper?
Apply for one of the trials that Stacy L. Cooper is conducting.
What is the office address of Stacy L. Cooper?
The office of Stacy L. Cooper is located at: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland 21287 United States. This is the address for their practice at the Johns Hopkins University/Sidney Kimmel Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.